Asco 2019 event analyser – low-key meeting belies some huge stock moves
Mirati Therapeutics nearly stole the show at Asco despite not actually presenting – a fact that illustrates how low on meaningful data this year's conference was.
Asco 2019 – Seattle sees an Adcetris follow-up on the horizon at last
A mid-stage study of enfortumab illustrates the relevance of nectin-4 in urothelial bladder cancer, and is hailed by experts as registrational.
Roxadustat safety analysis provokes more questions than answers
Fibrogen tumbles on a confusing safety update for its most advanced project.
Akebia plays spot the difference with investors
Questions about Akebia's disclosure of liver toxicity in a trial raise a red flag over vadadustat, the company's experimental anaemia treatment.
AACR 2019 – Xospata meets the conditions of its US approval
Survival data confirm the value of Astellas’s FLT3-targeting approach in acute myelogenous leukaemia.
Short the launch starts early for Urovant
For Urovant, beating placebo in a pivotal trial of vibegron was the easy part.
First big test approaches for Urovant
Six months after floating, Urovant is gearing up to release pivotal data on its most advanced overactive bladder project.
Are the big corporate venture arms retreating?
Funds backed by drugmakers remain visible contributors to the venture world, but several of the big corporate names seem to have reined in spending.
Asco-GU 2019 – Bayer and Orion have their work cut out with darolutamide
Results of the prostate cancer project’s pivotal Aramis trial, already known to be positive, are presented for the first time.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.